Mite-impermeable bed encasings,
does it really help with Reduced emergency-department attendance or admission for exacerbation in mite-sensitized children with asthma?
research showsThe grade is C with 56 points. In a 12-month trial of 284 mite-sensitized children, the single registered primary endpoint, the exacerbation rate over 12 months after randomization, was null. Hospital-attendance rates were 0.38 versus 0.52 (P=0.18), and prednisolone-course rates were 0.77 versus 0.85 (P=0.57). The event-based hospital-attendance result emphasized in the paper, 36/123 versus 49/118 with adjusted HR 0.55 (95% CI 0.36-0.85), was not the registered primary endpoint.
ads claimA mite barrier is not proof of broad symptom improvement. The supported claim is narrower: fewer repeat hospital attendances over one year in recently exacerbated, mite-sensitized children.
Useful facts when choosing a product
- The trial encased the mattress, duvet, and pillow, not the mattress alone.
- The comparator was a matched placebo cover, not no treatment.
- Verdict 1759 is D with 24 points and verdict 1758 is D with 35 points for different endpoints and interventions.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.house-dust-mite-impermeable-encasings.UNK.emergency-department-attendance-or-admission-for-exacerbation-in-mite-sensitized-children-with-asthma.reduce.placeboUnknown > House-dust-mite-impermeable encasings > Unknown > emergency-department attendance or admission for exacerbation in mite-sensitized children with asthma > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Children aged 3-17 with a recent hospital-treated asthma exacerbation and mite sensitization were randomized 146 versus 138 to active or matched placebo encasings and followed for 12 months. The registry's single primary endpoint was the exacerbation rate over 12 months after randomization. It was null: hospital-attendance rates were 0.38 versus 0.52, P=0.18, and prednisolone-course rates were 0.77 versus 0.85, P=0.57. The paper split results into event occurrence and emphasized positive hospital attendance at 36/123 versus 49/118, while prednisolone use was null at 60/123 versus 59/118; the event-based hospital endpoint was not the registered primary endpoint. Verdict 1759 shares the intervention family but not the original studies or participants. Funding came from the J. P. Moulton Charitable Foundation with infrastructure support from the North West Lung Centre Charity.
Why this is classified as C (56)
The single registered 12-month exacerbation-rate endpoint was null, while only a nonregistered event-based hospital result was positive, giving C with 56 points.
Counterpoint. The positive hospital endpoint must be reported alongside the null prednisolone and registered rate endpoints.
Rejudgment record. Cross-check applied — The single registered 12-month exacerbation-rate endpoint was null, and the positive event-based hospital endpoint was not the registered primary endpoint
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced hospital attendance for asthma exacerbation | B | Rates were 29.3% versus 41.5%, adjusted HR 0.55. |
| Reduced need for oral prednisolone during exacerbation | D | The result was null: 60/123 versus 59/118, HR 0.82 (95% CI 0.58-1.17). |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Murray CS et al. 2017 PAXAMA | Double-blind placebo-controlled randomized trial | 284 randomized (146/138); 241 in the 12-month event analysis (123/118) | J. P. Moulton Charitable Foundation; infrastructure support from North West Lung Centre Charity | Single registered primary endpoint: exacerbation rate over 12 months after randomization; the paper-emphasized event-based hospital outcome was not the registered primary | Hospital attendance 36/123 (29.3%) vs 49/118 (41.5%), adjusted HR 0.55 (0.36-0.85); prednisolone 60/123 (48.8%) vs 59/118 (50.0%), adjusted HR 0.82 (0.58-1.17) | Pivotal single confirmatory trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-08).
Final verification and publication gate: Codex · Evidence date: 2026-08-08 · Corrections: none
Cite this verdict
[Chamgap] Mite-impermeable bed encasings x reduced hospital use for asthma exacerbations — Evidence Grade C·56. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/mite-impermeable-bed-encasings-asthma-hospital-attendance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.